SHANGHAI, Dec. 8, 2025 /PRNewswire/ — J Hotel Shanghai Tower launches its festive season under the theme “Wish Upon a Star,” unveiling a series of holiday celebrations and elevated dining experiences high above the city. The season begins with a carol performance by the Wellington College International Shanghai choir, followed by the lighting of an 8-meter Christmas tree that illuminates a festive scene alongside a gingerbread house, the hotel’s signature crystal Shikumen, and Roman-inspired art installations, setting a magical, ceremony-filled atmosphere for guests.

The hotel’s signature restaurants and lounge offer a range of festive menus featuring Huaiyang cuisine, Japanese kaiseki, Cantonese classics, and modern international flavors. Seasonal ingredients, refined culinary craftsmanship and sweeping skyline views together to create memorable holiday experiences above the clouds.

120th Floor • Heavenly Jin — Festival Fine Dining Experience in the Clouds

Located on Floor 120 of the Shanghai Tower, 556 meters above ground, Heavenly Jin is “the highest restaurant in a building”, presenting exclusive festive dinners on Christmas Eve and New Year’s Eve. The seasonal menu highlights winter delicacies such as Boiled Water Chestnut and Meatball Soup, Braised Prawn with Rice Soup Cream and Sea Urchin, Braised Beef with Black Truffle Sauce and Taro, plus signatures items including Boiled Fish Tendon Soup with Pickled Chinese Artichoke, Braised American Lobster with Salty Egg Yolk Curry Sauce and Quinoa, and Braised Fish Maw with Shrimp Roe. Paired with sweeping nighttime views of the city, the experience feels both indulgent and unforgettable.

Christmas Eve Dinner for Two: RMB 4,588 (including beverages)
New Year’s Eve Dinner for Two: RMB 5,200 (including beverages)

104th Floor • Kinnjyou Inaka — A Kaiseki Celebration

On New Year’s Eve, Kinnjyou Inaka offers a seasonal kaiseki dinner featuring Snow Crab, Tuna, Baby Lobster, and M7 Australian Wagyu Beef, paired with by a comforting winter hotpot, an intimate, heartwarming experience above the clouds.

New Year’s Eve Kaiseki Dinner for Two: RMB 3,399

103rd Floor • Jin Yan — Refined Cantonese Festivities

Jin Yan offers a festive Cantonese set menu on December 31, crafted with daily-selected ingredients. Highlights include Double Boiled Conpoy with Vegetable and Matsutake Soup, Braised Baby Lobster with Minced Garlic, Braised Sea Cucumber and Flower Mushroom with Abalone Sauce, and Steamed Tiger Grouper and Mushroom with Soy Sauce, accompanied by nourishing dishes such as Soaked Green Vegetable and Bamboo Fungus in Superior Stock and Seafood Bisque with Noodles.

New Year’s Eve Set Menu for Two: RMB 3,399

101st Floor • Centouno — Global Festive Seafood Buffet

Centouno presents special Christmas Eve and New Year’s Eve seafood buffets, featuring oysters, tiger shrimp, spanner crab，sea conch, caviar and foie gras terrine; hot-station classics include Roasted Turkey, Beef Wellington, Roasted Australian Beef Sirloin and Honey Glazed Ham. Guests can also enjoy made-to-order Cheese-Grilled Rock Lobster, a selection of desserts and Mövenpick ice cream, along with a newly introduced winter hotpot that adds a comforting warmth to the holiday season.

Christmas Eve Buffet: RMB 638 per guest
New Year’s Eve Buffet for Two: RMB 2,026

84th Floor • Yi Lounge — New Year’s Countdown Party

Yi Lounge hosts a New Year’s Eve countdown party on December 31, with panoramic views of the Bund and Huangpu River. Guests can enjoy free-flow Champagne, Balvenie Port Wood 21 Years and Martell Xo, bar snacks, live music, and close-up magic entertainment, a vibrant and celebratory way to welcome the new year.

Party packages from RMB 588 per person

1st Floor • Café & Patisserie — Festive Gift Hampers

The hotel’s Café & Patisserie offers curated festive hampers through December 31, containing Sonovia Iberian Ham, Sicilia Virgin Olive Oil, panettone, Maccaroneria Pasta, Stolen, chocolates, and macarons, perfect for thoughtful seasonal gifting.

Festive Hamper: RMB 1,288 per set

For festival dining reservations and gift purchases, please call +86 21 3886 8989 at least two days in advance. All prices are subject to a 15% service charge. For a memorable stay experience above the clouds, visit the official Jin Jiang Rewards, Radisson Rewards, www.jhotel-shanghai.com or contact info@jhotel-shanghai.com.

ABOUT JIN JIANG RADISSON HOTELS

Established under Jin Jiang International Group, Jin Jiang Radisson Hotels is a business structure formed by Jin Jiang International Hotel Management Co., Ltd. and Radisson Hotel Group China. Jin Jiang Radisson Hotels provides a complete hospitality solution for luxury and high-end hotels, creating outstanding value and exceptional stay experience for guests while meeting the evolving needs of tourism industry.

The portfolio of Jin Jiang Radisson Hotels comprises of 10 brands: J, Yan Garden, Kunlun, Jin Jiang Hotel, Radisson Collection, Radisson Blu, Radisson, Radisson Individuals, Park Plaza, and Golden Tulip.

Jin Jiang Radisson Hotels offers dual loyalty programs: Jin Jiang Rewards and Radisson Rewards, tailormade for domestic and international guests. Our loyalty programs are designed to deliver an elevated experience that makes Every Moment Matter, offering exclusive privileges and benefits to our valued members.

ABOUT J

Above All Else

J is an important milestone for Jin Jiang International being the first Chinese company successfully developed a top-of-class “Chinese global brand”. Meticulously crafted over the course of years, J brand inherits the essence of “Benevolence” advocated by Chinese Confucianism, conveying the cultural sentiment of “Like a Gentleman, with a Benevolent Heart”.

The letter “J” is derived from the phonetic sound of the Chinese character “锦” (Jin), sharing the same initial letter as “Jin Jiang”, thereby reflecting the close connection between the J brand and the Jin Jiang brand. The design inspiration for the J logo originates from the blooming magnolia, the official flower of Shanghai. The goal of J is to establish itself as a top global Chinese hotel brand positioned at the pinnacle of global hotel brands, originating from Shanghai and blooming worldwide.

Source

SHANGHAI, Dec. 8, 2025 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that clinical data from its allogeneic BCMA-targeted CAR T-cell product candidate, CT0596, for the treatment of relapsed/refractory multiple myeloma (R/R MM) was presented in a poster at the 67th American Society of Hematology (ASH) Annual Meeting. The poster was titled “A First-in-Human Study of CT0596, an Allogeneic CAR T-Cell Therapy Targeting BCMA, in Patients with Relapsed/Refractory Multiple Myeloma.” The publication number was 2296.

This clinical trial (NCT06718270) enrolled 8 patients with R/R MM in the dose-escalation phase who received CT0596 infusion. The median number of prior lines of therapy was 4.5 (range: 3-9). Enrollment was not restricted by NKG2A expression levels. Regarding lymphodepletion, 6 patients received full-dose lymphodepletion with fludarabine (30 mg/m²/day) and cyclophosphamide (500 mg/m²/day) for 3 consecutive days, while 2 patients received reduced-dose lymphodepletion. CT0596 was administered at dose levels of 1.5×10⁸ (n=1), 3×10⁸ (n=5), and 4.5×10⁸ CAR-T cells (n=2), with one patient receiving two infusions.

As of August 31, 2025, all 8 infused patients were evaluable for efficacy, with a median follow-up of 4.14 months (range: 0.9-7.9 months). Six patients achieved a partial response (PR) or better: 3 achieved complete response/stringent complete response (CR/sCR) (all in the full-dose lymphodepletion group), 1 achieved very good partial response (VGPR), and 2 achieved PR. Among the 6 patients who received full-dose lymphodepletion, 5 achieved PR or better. Six patients in the full-dose lymphodepletion group achieved minimal residual disease (MRD)-negativity at Week 4. Patient 01 maintained ongoing sCR and MRD-negativity as of Month 8. Patient 04 achieved PR with resolution of extramedullary disease following the second infusion. CAR-T cell expansion was observed in all 8 patients. Among the two patients who received the 4.5×10⁸ dose, one achieved sCR, and the other exhibited deepening response to VGPR.

CT0596 demonstrated a manageable safety profile. Four patients experienced Grade 1 cytokine release syndrome (CRS); no Grade 2 or higher CRS was observed. No immune effector cell-associated neurotoxicity syndrome (ICANS) or graft-versus-host disease (GVHD) was reported. No dose-limiting toxicities, treatment discontinuations, or deaths were observed.

The study is still in the dose-exploration phase. The lymphodepletion regimen has been determined, and higher cell doses are being explored to further define the recommended dose (RD). The company plans to initiate a Phase 1b registrational study for CT0596 in 2026.

About CT0596

CT0596 is an allogeneic BCMA-targeted CAR-T therapy developed using CARsgen’s proprietary THANK-u Plus™ platform. It is currently being evaluated in investigator-initiated trials for relapsed/refractory multiple myeloma (R/R MM) or plasma cell leukemia (PCL). CT0596 demonstrated preliminary favorable tolerability and encouraging efficacy signals. Further investigation is planned in additional plasma cell malignancies and autoimmune diseases mediated by autoreactive plasma cells. The company anticipates submitting an Investigational New Drug (IND) application in the second half of 2025.

About CARsgen Therapeutics Holdings Limited

CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen’s mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable.

Forward-looking Statements

All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group’s current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group’s control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading “Principal Risks and Uncertainties” in our most recent annual report and interim report and other announcements and reports made available on our corporate website, https://www.carsgen.com. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release.

Source

Sustained Worldwide Outreach Drives Greater Collaboration Opportunities

BEIJING, Dec. 7, 2025 /PRNewswire/ — The 4^th China International Supply Chain Expo (“CISCE,” “the Expo”) will be held in Beijing from June 22 to 26, 2026. To date, more than 300 companies have signed up to exhibit, with preparations moving forward smoothly.

From November 30 to December 2, a delegation of Chinese business leaders organized by the China Council for the Promotion of International Trade (CCPIT) visited Canada, engaging in broad exchanges with government and industry representatives. At the Canada-China Forum on Trade and Investment Cooperation, the group gave a presentation on the upcoming Expo to over 150 government officials, institutional leaders, and corporate executives from both countries. Discussions centered on deepening collaboration in advanced manufacturing, digital technology, clean energy, and sustainable agriculture.

Following this, the CCPIT dispatched a delegation to the United States, engaging in extensive dialogues with American political and business leaders while conducting multiple promotional events across the country. On December 4, in Washington, D.C., CCPIT President Ren Hongbin addressed the forum “From Policy to Partnership: APEC 2026 – Unlocking Trade and Investment Potential.” He noted the reciprocal benefits of U.S.-China commercial relations while reaffirming CCPIT’s role in deepening practical cooperation and promoting the steady and long-term development of bilateral economic and trade ties. U.S. attendees showed considerable interest in strengthening supply chain ties with China. During the forum, the China International Exhibition Center Group delivered a dedicated presentation on the 4^th CISCE.

On December 5, the delegation attended the “Port of Opportunity: U.S.-China Business Networking Breakfast” in Oakland, California, focusing on digital technology, artificial intelligence, and other emerging sectors, to explore joint innovation opportunities within the two countries’ industrial ecosystems. Another detailed presentation on the 4^th CISCE was also shared.

The Expo has become a vital platform for advancing international cooperation in global industrial and supply chains. The China Council for the Promotion of International Trade stated that it will continue to adhere to the strategic guidance of the 15th Five-Year Plan, ensuring high standards and superior quality in all preparations for the fourth edition of the Expo.

Please visit https://en.cisce.org.cn/ for more up-to-date news about the 4^th China International Supply Chain Expo.

Source

SHANGHAI, Dec. 7, 2025 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced today announced with great pleasure that its independently developed fully human BCMA-targeted CAR-T product, zevorcabtagene autoleucel (zevor-cel, R&D code: CT053), has been included in China’s Commercial Health Insurance Innovative Drug Catalogue (2025) (referred to as the “Innovative Drug Catalogue”) for the treatment of relapsed/refractory multiple myeloma. The Innovative Drug Catalogue was released today at a press conference held by the National Healthcare Security Administration (NHSA) in Guangzhou. Dr. Huamao Wang, Co-founder and Chief Operating Officer of CARsgen, attended the conference.

This year, the NHSA took the landmark step of establishing the Innovative Drug Catalogue, operating alongside the Basic Medical Insurance Catalogue. This Innovative Drug Catalogue specifically targets drugs that are highly innovative, of significant clinical value, and deliver substantial patient benefits. It is designed to empower the innovative drug industry chain with unprecedented support and enhance drug accessibility.

Zevor-cel is a Category 1 innovative biological product with its Marketing Authorization (MA) held by CARsgen Life Sciences Co., Ltd., a subsidiary of CARsgen Therapeutics. It is manufactured by CARsgen Pharmaceuticals Co., Ltd. Zevor-cel was approved for marketing by the National Medical Products Administration (NMPA) on February 23, 2024, for the treatment of adult patients with relapsed or refractory multiple myeloma who have progressed after at least 3 prior lines of therapy (including a proteasome inhibitor and an immunomodulatory agent).

CARsgen has granted exclusive commercialization rights for zevor-cel in mainland China to Huadong Medicine Co., Ltd. (Stock Code: 000963.SZ). Huadong Medicine has established a dedicated, professional, and comprehensive commercial team to promote the use of zevor-cel and has been utilizing China’s multi-layered insurance system to improve patient accessibility. Currently, certification and regulatory filings for zevor-cel have been completed in more than 20 provinces and municipalities across China. From January to September 2025, CARsgen received 170 confirmed orders from Huadong Medicine, exceeding the total number of orders for the full year of 2024.

Five-year follow-up results from the Phase I clinical trial of zevor-cel, presented at the 2025 IMS Annual Meeting, demonstrated a manageable safety profile and deep, durable efficacy in patients with relapsed/refractory multiple myeloma. No grade 3 or higher cytokine release syndrome (CRS) was observed. No immune effector cell-associated neurotoxicity syndrome (ICANS), delayed neurotoxicities, second primary malignancy, or other delayed adverse events was observed. The overall response rate was 100% (95% CI: 76.8, 100.0) with 11 (78.6%) patients achieving complete response (CR) or stringent complete response (sCR). All patients who achieved CR or better were minimal residual disease (MRD) negative at 10⁻⁵ threshold. The median progression-free survival (mPFS) and the median duration of response (mDoR) were 44.1 months and 43.2 months in CR/sCR patients, respectively. The median overall survival (mOS) was not reached. The patient survival rate at 60 months post-infusion was 76.9%.

Dr. Huamao Wang, Co-founder and Chief Operating Officer of CARsgen, said: “We are very pleased to see zevor-cel included in the first batch of the Innovative Drug Catalogue. This reflects the nation’s high recognition of and policy support for innovative drugs. This inclusion will help further alleviate the financial burden on patients and enhance the accessibility of advanced cell therapies, allowing more patients to benefit from innovative treatments. CARsgen remains committed to addressing unmet clinical needs, developing more innovative and differentiated CAR T-cell products, bringing them to patients as quickly as possible, and contributing to the ‘Healthy China’ initiative.”

About CARsgen Therapeutics Holdings Limited

CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen’s mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable.

Forward-looking Statements

All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group’s current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group’s control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading “Principal Risks and Uncertainties” in our most recent annual report and interim report and other announcements and reports made available on our corporate website, https://www.carsgen.com. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release.

Contact CARsgen

For more information, please visit https://www.carsgen.com/

Source

HONG KONG, Dec. 7, 2025 /PRNewswire/ — For the millions of programmers, creative professionals, and remote workers battling the inertia of sedentary work, a breakthrough moment has arrived. LiberNovo, the company pioneering the next generation of workspace solutions, today announced the global, full-inventory launch of the LiberNovo Omni – the world’s first dynamic ergonomic office chair designed to adapt to your body’s every micro-movement.

The Omni is now ready-to-ship across five major regions — the US, Canada, the EU, Germany, and the UK. This milestone elevates LiberNovo from a fast-growing regional player to a multi-continent operator, opening a new era in health-focused workspaces.

The announcement follows LiberNovo’s recent high-profile presence at the Global AI Pitch Summit Silicon Valley 2025, where the brand officially introduced its future-forward vision for health-first design powered by intelligent motion.

No Waiting: The Global Shift to Instant Ergonomics

Recognizing the global urgency for sitting-pain relief, LiberNovo has synchronized fulfillment across North America and Europe, enabling consumers to order and receive the Omni without lead times. The shift from pre-order to in-stock availability positions LiberNovo as a provider capable of delivering next-generation comfort on demand to engineers, designers, gamers, and hybrid workers alike.

Dynamic Ergonomics — Support Defined by Motion

The rise of long-hour remote work has proven that traditional, static seating is insufficient. Professionals are searching for the best ergonomic chair, but need a solution that can keep up with long hours. They demand the user conform to a fixed ‘ideal’ posture. LiberNovo Omni shifts the focus from fixed posture to Dynamic Ergonomics: support that adapts to natural movement.

Key innovations:

• Dynamic Support System — Real-time adaptive support that aligns head, spine, elbows, and hips through natural motion.
• Bionic FlexFit Backrest — 16 joints + 8 adaptive panels form a responsive S-curve that mimics the spine to relieve long-hour pressure.
• Four Intelligent Modes — Work / Entertainment / Meeting / Recovery — fluid transitions for different daily states.
• Deep Spinal Recovery Recline（160° ） — Decompression positioning designed to restore mobility and release tension.
• Intuitive Adjustability — 4D armrests, 3D neck support, adjustable seat height & recline, optional footrest for personal fit.

Together, these advancements position LiberNovo as a complete next-generation ergonomic upgrade, a meaningful alternative for users seeking comfort, pain relief, and more sustainable work-life health.

Silicon Valley AI Summit — Where Technology Meets Health

At the Global AI Pitch Summit in Silicon Valley, LiberNovo shared more than a product — it presented a vision for how AI, Dynamic Ergonomics, and health-first workspace design will redefine the future of knowledge work. Representing the emergence of motion-based ergonomics in the AI era, LiberNovo participated as an official sponsor, contributing thought leadership on how intelligent support systems can reduce the physical cost of long-hour digital labor and unlock healthier productivity at scale.

Over two days of dialogue with researchers, founders, and workplace innovators, the conversation focused on a critical shift: from static sitting to adaptive, responsive work environments. LiberNovo hosted a 45-minute expert panel exploring AI & occupational health, the body’s reactivation in the sedentary era, and why dynamic support will become foundational in smart workspaces. A live keynote and product demo further illustrated how the LiberNovo Omni responds to micro-movements in real time—showing a tangible pathway toward AI-interactive ergonomics that support the body intuitively, not reactively.

This moment signaled more than a presence on stage. It positioned LiberNovo at the intersection of AI × wellness × human-centered workspace innovation, establishing the brand as a key voice in the next chapter of work—where health is not an afterthought but a core design principle for future tools and environments.

Christmas & New Year Sale (US/CA) — December 6 to January 5

To celebrate the global launch, LiberNovo is offering a limited seasonal promotion:

United States (PST)

• Up to 30% OFF flagship products
• Free 6-piece Christmas Gift Pack for first 1,000 orders (>$800)
• 30-day Price Match Guarantee
• Klarna Pay-in-4, 0% APR
• +500 registration points & double VIP points

Canada (EST)

• Up to 34% OFF flagship products
• Free gift pack for first 500 orders (>C$1,200)
• 30-day Price Match Guarantee
• Afterpay Pay-in-4, 0% APR
• +500 registration points & double VIP points

Gift Pack Includes: silk eye mask, eco-friendly tote bag, blanket, coffee mug, StepSync mat, and a scratch-resistant cushion cover.

Beyond the Chair: Redefining Future Workspaces

This launch is more than a holiday event; it signals a fundamental shift in occupational health. By successfully uniting health-first design and a seamless global ready-to-ship network, LiberNovo is evolving beyond a chair brand. The company is now positioned as a future workspace innovator, dedicated to delivering comprehensive, next-generation solutions for the modern, demanding work life.

Learn more at libernovo.com and experience a smarter, healthier way to sit.

Source